Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies
Tae‐Min Kim(Catholic Medical Center), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Xu Zhu(Children's Hospital of Chongqing Medical University), Yazeed Sawalha(Cleveland Clinic), Dok Hyun Yoon(Ulsan College), Aravind Ramakrishnan(Fred Hutch Cancer Center), Koji Izutsu(Tokyo National Hospital), Don A. Stevens(Norton Healthcare), Constantine S. Tam(The Alfred Hospital), Ryan Jacobs(Levine Cancer Institute), Dai Maruyama(National Cancer Center), Sumana Devata(Medical College of Wisconsin), Denise Brennan(Arrakis Therapeutics (United States)), Matthew J. Matasar(Rutgers, The State University of New Jersey), David Sermer, Robin Lesley(San Francisco Public Library), Sameh Gaballa(Johns Hopkins Hospital), Mihail Obrocea(AstraZeneca (Japan)), Hisayuki Yokoyama(Sendai Medical Center), Jin Seok Kim(University of Ulsan), Won-Seog Kim(Samsung Medical Center), Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Jing‐Zhou Hou(Center for Cancer and Blood Disorders), Ming-Chung Wang(Kaohsiung Chang Gung Memorial Hospital), Eliza A. Hawkes(La Trobe University)
Cited by 2
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k